.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,858,616

« Back to Dashboard

Details for Patent: 6,858,616

Title: Nitrogen containing heterobicycles as factor Xa inhibitors
Abstract:The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
Inventor(s): Fevig; John M. (Lincoln University, PA), Cacciola; Joseph (Newark, DE), Clark; Charles G. (Cherry Hill, NJ), Han; Qi (Hockessin, DE), Lam; Patrick Yuk Sun (Chadds Ford, PA), Pinto; Donald J. P. (Kennett Square, PA), Pruitt; James R. (Landenberg, PA), Quan; Mimi L. (Newark, DE), Rossi; Karen A. (Boothwyn, PA)
Assignee: Bristol-Myers Squibb Pharma Company (Princeton, NJ)
Filing Date:Apr 26, 2002
Application Number:10/133,998
Claims:1. A compound selected from the group: ##STR238## or a sterioisomer or pharmaceutically acceptable salt thereof, wherein compounds of the above formulas are substituted with 0-2 R.sup.3 ; G is a group of formula I or II: ##STR239## ring D is selected from --(CH.sub.2).sub.3 --, --(CH.sub.2).sub.4 --, --CH.sub.2 N.dbd.CH--, --CH.sub.2 CH.sub.2 N.dbd.CH--, and a 5-6 membered aromatic system containing from 0-2 heteroatoms selected from the group N, O, and S, provided that from 0-1 O and S atoms are present; ring D, when present, is substituted with 0-2 R; E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, substituted with 0-1 R; R is selected from Cl, F, Br, 1, OH, C.sub.1-3 alkoxy, NH.sub.2, NH(C.sub.1-3 alkyl), N(C.sub.1-3 alkyl).sub.2, CH.sub.2 NH.sub.2, CH.sub.2 NH(C.sub.1-3 alkyl), CH.sub.2 N(C.sub.1-3 alkyl).sub.2, CH.sub.2 CH.sub.2 NH.sub.2, CH.sub.2 CH.sub.2 NH(C.sub.1-3 alkyl), and CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2 ; alternatively, ring D is absent; when ring D is absent, ring E is selected from phenyl, pyridyl, pyrimidyl, pyrazinyl, and pyridazinyl, and ring E is substituted with R" and R'; R" is selected from F, Cl, Br, I, OH, C.sub.1-3 alkoxy, CN, C(.dbd.NR.sup.8)NR.sup.7 R.sup.9, NHC(.dbd.NR.sup.8)NR.sup.7 R.sup.9, NR.sup.8 CH(.dbd.NR.sup.7), C(O)NR.sup.7 RB, (CR.sup.8 R.sup.9).sub.t NR.sup.7 R.sup.8, SH, C.sub.1-3 alkyl-S, S(O)R.sup.3b, S(O).sub.2 R.sup.3a, S(O).sub.2 NR.sup.2 R.sup.2a, and OCF.sub.3 ; R' is selected from H, F, Cl, Br, I, SR.sup.3, CO.sub.2 R.sup.3, NO.sub.2, (CH.sub.2).sub.t OR.sup.3, C.sub.1-4 alkyl, OCF.sub.3, CF.sub.3, C(O)NR.sup.7 R.sup.8, and (CR.sup.8 R.sup.9).sub.t NR.sup.7 R.sup.8 ; alternatively, R" and R' combine to form methylenedioxy or ethylenedioxy; Z is N or CR.sup.1a ; Z.sup.1 is S, O, or NR.sup.3 ; Z.sup.2 is selected from H, C.sub.1-4 alkyl, phenyl, benzyl, C(O)R.sup.3, and S(O).sub.p R.sup.3c ; R.sup.1a is selected from H, --(CH.sub.2).sub.r -R.sup.1 ', --CH.dbd.CH-R.sup.1 ', NHCH.sub.2 R.sup.1 ", OCH.sub.2 R.sup.1 ", SCH.sub.2 R.sup.1 ", NH(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1 ', O(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1 ', and S(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1 '; R.sup.1 ' is selected from H, C.sub.1-3 alkyl, F, Cl, Br, I, --CN, --CHO, (CF.sub.2).sub.r CF.sub.3, (CH.sub.2).sub.r OR.sup.2, NR.sup.2 R.sup.2a, C(O)R.sup.2c, OC(O)R.sup.2, (CF.sub.2).sub.r CO.sub.2 R.sup.2 C, S(O).sub.p R.sup.2b, NR.sup.2 (CH.sub.2).sub.r OR.sup.2, C(.dbd.NR.sup.2 C)NR.sup.2 R.sup.2a, NR.sup.2 C(O)R.sup.2b, NR.sup.2 C(O)R.sup.3, NR.sup.2 C(O)NHR.sup.2b, NR.sup.2 C(O).sub.2 R.sup.2a, OC(O)NR.sup.2a R.sup.2b, C(O)NR.sup.2 R.sup.2a, C(O)NR.sup.2 (CH.sub.2).sub.r OR.sup.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 R.sup.2b, C.sub.3-6 carbocyclic residue substituted with 0-2 R.sup.4a, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4a ; R" is selected from H, CH(CH.sub.2 OR.sup.2).sub.2, C(O)R.sup.2c, C(O)NR.sup.2 R.sup.2a, S(O)R.sup.2b, S(O).sub.2 R.sup.2b, and SO.sub.2 NR.sup.2 R.sup.2a ; R.sup.2, at each occurrence, is selected from H, CF.sub.3, C.sub.1-6 alkyl, benzyl, C.sub.3-6 carbocyclic residue substituted with 0-2 R.sup.4b, a C.sub.3-6 carbocyclic-CH.sub.2 -- residue substituted with 0-2 R.sup.4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4b ; R.sup.2a, at each occurrence, is selected from H, CF.sub.3, C.sub.1-6 alkyl, benzyl, C.sub.3-6 carbocyclic residue substituted with 0-2 R.sup.4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4b ; R.sup.2b, at each occurrence, is selected from CF.sub.3, C.sub.1-4 alkoxy, C.sub.1-6 alkyl, benzyl, C.sub.3-6 carbocyclic residue substituted with 0-2 R.sup.4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4b ; R.sup.2c, at each occurrence, is selected from CF.sub.3, OH, C.sub.1-4 alkoxy, C.sub.1-6 alkyl, benzyl, C.sub.3-6 carbocyclic residue substituted with 0-2 R.sup.4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4b ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R.sup.4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S; R.sup.3, at each occurrence, is selected from H, C.sub.1-4 alkyl, and phenyl; R.sup.3a, at each occurrence, is selected from H, C.sub.1-4 alkyl, and phenyl; R.sup.3b, at each occurrence, is selected from H, C.sub.1-4 alkyl, and phenyl; R.sup.3c, at each occurrence, is selected from C.sub.1-4 alkyl, and phenyl; A is selected from: C.sub.3-10 carbocyclic residue substituted with 0-2 R.sup.4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R.sup.4 ; B is selected from: Y, X-Y, C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, and NR.sup.2 C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a ; X is selected from C.sub.1-4 alkylene, --CR.sup.2 (CR.sup.2 R.sup.2b)(CH.sub.2).sub.t --, --C(O)--, --C(.dbd.NR.sup.1 ")-, --CR.sup.2 (NR.sup.1 "R.sup.2)--, --CR.sup.2 (OR.sup.2)--, --CR.sup.2 (SR.sup.2, --C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O), --S(O).sub.p --, --S(O).sub.p CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a S(O).sub.p --, --S(O).sub.2 NR.sup.2 --, --NR.sup.2 S(O).sub.2 --, --NR.sup.2 S(O).sub.2 CR.sup.2 R.sup.2a, --CR.sup.2 R.sup.2a S(O).sub.2 NR.sup.2 --, --NR.sup.2 S(O).sub.2 NR.sup.2 --, --C(O)NR.sup.2 --, --NR.sup.2 C(O), --C(O)NR.sup.2 CR.sup.2 R.sup.2a --, --NR.sup.2 C(O)CR.sup.2 R.sup.2a -, --CR.sup.2 R.sup.2a C(O)NR.sup.2 --, --CR.sup.2 R.sup.2a NR.sup.2 C(O)--, --NR.sup.2 C(O)O--, --OC(O)NR.sup.2 --, --NR.sup.2 C(O)NR.sup.2 --, --NR.sup.2 --, --NR.sup.2 CR.sup.2 R.sup.2a, CR.sup.2 R.sup.2a NR.sup.2, O, --CR.sup.2 R.sup.2a O--, and --OCR.sup.2 R.sup.2a --; Y is selected from: CH.sub.2 NR.sup.2 R.sup.2a ; CH.sub.2 CH.sub.2 NR.sup.2 R.sup.2a ; C.sub.3-10 carbocyclic residue substituted with 0-2 R.sup.4a, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with O.sub.2 R.sup.4a ; R.sup.4, at each occurrence, is selected from H, .dbd.O, (CH.sub.2).sub.r OR.sup.2, F, Cl, Br, 1, C.sub.1-4 alkyl, --CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2c NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, C(.dbd.NS(O).sub.2 R.sup.5)NR.sup.2 R.sup.2a, NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, C(O)NHC(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.2 SO.sub.2 R.sup.5, S(O).sub.p R.sup.5, (CF.sub.2).sub.r CF.sub.3, NCH.sub.2 R.sup.1 ", OCH.sub.2 R.sup.1 ", SCH.sub.2 R.sup.1 ", N(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1 ', O(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1 ', and S(CH.sub.2).sub.2 (CH.sub.2).sub.t R.sup.1 '; alternatively, one R.sup.4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S; R.sup.4a, at each occurrence, is selected from H, .dbd.O, (CH.sub.2).sub.r OR.sup.2, (CH.sub.2).sub.r --F, (CH.sub.2).sub.r -Br, (CH.sub.2).sub.r --Cl, Cl, Br, F, I, C.sub.4 alkyl, --CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2 C, NR.sup.2 C(O)R.sup.2b, C(O)NR.sup.2 R.sup.2a, (CH.sub.2).sub.r N.dbd.CHOR.sup.3, C(O)NH(CH.sub.2).sub.2 NR.sup.2 R.sup.2a, NR.sup.2 C(O)NR.sup.2 R.sup.2a, C(.dbd.NR.sup.2)NR.sup.2 R.sup.2a, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 --C.sub.1-4 alkyl, C(O)NHSO.sub.2 --C.sub.1-4 alkyl, NR.sup.2 SO.sub.2 R.sup.5, S(O).sub.p R.sup.5, and (CF.sub.2).sub.r CF.sub.3 ; alternatively, one R.sup.4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R.sup.5 ; R.sup.4b, at each occurrence, is selected from H, .dbd.O, (CH.sub.2).sub.r OR.sup.3, F, Cl, Br, I, C.sub.1-4 alkyl, --CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.3 R.sup.3a, (CH.sub.2).sub.r C(O)R.sup.3, (CH.sub.2).sub.r C(O)OR.sup.3c, NR.sup.3 C(O)R.sup.3a, C(O)NR.sup.3 R.sup.3a, NR.sup.3 C(O)NR.sup.3 R.sup.3a, C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, NR.sup.3 C(.dbd.NR.sup.3)NR.sup.3 R.sup.3a, SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 NR.sup.3 R.sup.3a, NR.sup.3 SO.sub.2 --C.sub.1-4 alkyl, NR.sup.3 SO.sub.2 CF.sub.3, NR.sup.3 SO.sub.2 -phenyl, S(O).sub.p CF.sub.3, S(O).sub.p -C.sub.1-4 alkyl, S(O).sub.p -phenyl, and (CF.sub.2).sub.r CF.sub.3 ; R.sup.5, at each occurrence, is selected from CF.sub.3, C.sub.1-6 alkyl, phenyl substituted with 0-2 R.sup.6, and benzyl substituted with 0-2 R.sup.6 ; R.sup.6, at each occurrence, is selected from H, OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, CN, NO.sub.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, (CH.sub.2).sub.r C(O)R.sup.2b, NR.sup.2 C(O)R.sup.2b, NR.sup.2 C(O)NR.sup.2 R.sup.2a, C(.dbd.NH)NH.sub.2, NHC(.dbd.NH)NH.sub.2, SO.sub.2 NR.sup.2 R.sup.2a, NR.sup.2 SO.sub.2 NR.sup.2 R.sup.2a, and NR.sup.2 SO.sub.2 C.sub.1-4 alkyl; R.sup.7, at each occurrence, is selected from H, OH, C.sub.1-6 alkyl, C.sub.1-6 alkylcarbonyl, C.sub.1-6 alkoxy, C.sub.1-4 alkoxycarbonyl, (CH.sub.2).sub.n -phenyl, C.sub.6-10 aryloxy, C.sub.6-10 aryloxycarbonyl, C.sub.6-10 arylmethylcarbonyl, C.sub.1-4 alkylcarbonyloxy C.sub.1-4 alkoxycarbonyl, C.sub.6-10 arylcarbonyloxy C.sub.1-4 alkoxycarbonyl, C.sub.1-6 alkylanocarbonyl, phenylaminocarbonyl, and phenyl C.sub.1-4 alkoxycarbonyl; R.sup.8, at each occurrence, is selected from H, C.sub.1-6 alkyl and (CH.sub.2).sub.n -phenyl; alternatively, R.sup.7 and R.sup.8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S; R.sup.9, at each occurrence, is selected from H, C.sub.1-6 alkyl and (CH.sub.2).sub.n -phenyl; n, at each occurrence, is selected from 0, 1, 2, and 3; m, at each occurrence, is selected from 0, 1, and 2; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, and 3; s, at each occurrence is selected from 0, 1, and 2; and, t, at each occurrence is selected from 0, 1, 2, and 3.

2. A compound of claim 1, wherein the compound is selected from the group: ##STR240## wherein compounds of the above formulas are substituted with 0-2 R.sup.3 ; G is selected from the group: ##STR241## ##STR242## ##STR243## A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R.sup.4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrirnidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzioidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; B is selected from: Y and X-Y; X is selected from C.sub.1-4 alkylene, --C(O)--, --C(.dbd.NR.sup.1 ")--, --CR.sup.2 (NR.sup.1 "R.sup.2)--, --C(O)CR.sup.2 R.sup.2a --, --CR.sup.2 R.sup.2a C(O), --C(O)NR.sup.2 --, --NR.sup.2 C(O)--, C(O)NR.sup.2 CR.sup.2 R.sup.2a, --NR.sup.2 C(O)CR.sup.2 R.sup.2a, --CR.sup.2 R.sup.2a C(O)NR.sup.2 --, CR.sup.2 R.sup.2a NR.sup.2 C(O), --NR.sup.2 C(O)NR.sup.2 --, --NR.sup.2 --, --NR.sup.2 CR.sup.2 R.sup.2a, CR.sup.2 R.sup.2a NR.sup.2, O, CR.sup.2 R.sup.2a O--, and --OCR.sup.2 R.sup.2a --; Y is C.sub.2 NR.sup.2 R.sup.2a or CH.sub.2 CH.sub.2 N.sup.2 R.sup.2a ; alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems that are substituted with 0-2 R.sup.4a ; cyclopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyffolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1,2,3-oxadiazolyl, 1,2,4 oxadiazolyl, 1,2,5 oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-thliadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 11,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl; alternatively, Y is selected from the following bicyclic heteroaryl ring systems: ##STR244## K is selected from O, S, NH, and N; and, s is 0.

3. A compound of claim 2, wherein G is selected from the group: ##STR245## ##STR246##

4. A compound of claim 3, wherein: G is selected from: ##STR247##

5. A compound of claim 4, wherein: A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R.sup.4 ; and, B is selected from X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R.sup.4a ; R.sup.2, at each occurrence, is selected from H, CH.sub.3, CH.sub.2 CH.sub.3, cyclopropylmethyl, cyclobutyl, and cyclopentyl; R.sup.2a, at each occurrence, is H or CH.sub.3 ; alternatively, R.sup.2 and R.sup.2a, together with the atom to which they are attached, combine to form pyrrolidine substituted with O.sub.2 R.sup.4b ; R.sup.4, at each occurrence, is selected from OH, (CH.sub.2).sub.r OR.sup.2, halo, C.sub.1-4 alkyl, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, and (CF.sub.2).sub.r CF.sub.3 ; R.sup.4a is selected from CIA alkyl, CF.sub.3, (CH.sub.2).sub.r OR.sup.2, (CH.sub.2).sub.r NR.sup.2 R.sup.2a, S(O).sub.p R.sup.5, SO.sub.2 NR.sup.2 R.sup.2a, and 1-CF.sub.3 -tetrazol-2-yl; R.sup.4b, at each occurrence, is selected from H, CH.sub.3, and OH; R.sup.5, at each occurrence, is selected from CF.sub.3, C.sub.1-6 alkyl, phenyl, and benzyl; X is CH.sub.2 or C(O); Y is selected from pyrrolidino and morpholino; and, r, at each occurrence, is selected from 0, 1, and 2.

6. A compound of claim 5, wherein: A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F-phenyl, 2-methylphenyl, 2-aminophenyl, and 2-methoxyphenyl; and, B is selected from the group: 2-(aminosulfonyl)phenyl, 2-(methylaminosulfonyl)phenyl, 1-pyrrolidinocarbonyl, 2-(methylsulfonyl)phenyl, 2-(N,N-dimethylaminomethyl)phenyl, dimethylaminomethyl)phenyl, 2-(N-pyrrolidinylmethyl)phenyl, 1-methyl-2-imidazolyl, 2-methyl-1-imidazolyl, 2-(dimethylaminomethyl)-1-imidazolyl, 2-(N-(cyclopropylmethyl)aminomethyl)phenyl, 2-(N-(cyclobutyl)aminomethyl)phenyl, 2-(N-(cyclopentyl)aminomethyl)phenyl, and 2-(N-(3-hydroxypyrrolidinyl)methyl)phenyl.

7. A compound of claim 1, wherein the compound is selected from: 1-[4-Methoxyphenyl]-3-cyano-6-[2'-methylsulfonyl-3-fluoro-[1,1']-biphen-4-y l]-1,4-dihydropyrazolo-[4,3-d]-pyrimidine-5,7-dione; 1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-6-[2'-aminosulfonyl-3-fluoro-[1, 1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2'-aminosulfonyl-3-fluoro-[1,1]-bi phen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(methoxycarbonyl)-6-[2'-aminosulfonyl-[1,1']-biphen-4 -yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-6-[2'-aminosulfonyl-[1,1']-biphen-4-yl]-1,6-dihydropyra zolo-[4,3-d]-pyrimidin-7-one-3-carboxylic acid; 1-[4-Methoxyphenyl]-3-(aminocarbonyl).sub.6 -[2'-aminosulfonyl-[1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimid in-7-one; 1-[4-Methoxyphenyl]-3-cyano-6-[2'-aminosulfonyl-[1,1']-biphen-4-yl]-1,6-dih ydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminomethyl)-6-[2'-aminosulfonyl-[1,1']-biphen-4-yl- 1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6[4-(2-methylimidazol-1'-yl)phenyl]- 1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[4-(2-methylimidazol-1'-yl)phenyl]- 1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2'-N-pyrrolidinylmethyl-[1,1' ]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2'-N-pyrrolidinylmethyl-[1,1' ]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-12'-N-pyrrolidinylmethyl-[1,1']-bip hen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-cyano-6-[2'-N-pyrrolidinylmethyl-[1,1']-biphen-4-yl]- 1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2-fluoro-4-(2-dimethylaminomethyl imidazol-1'-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[2-Aminomethylphenyl]-3-(ethoxycarbonyl)-6-[2'-methylsulfonyl-[1,1']-biph en-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl] 3-cyano-6-[2'-N,N-dimethylaminomethyl-[1,1']-biphen-4-yl]-1,6-dihydropyraz olo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-cyano-5-methyl-6-[2'-N,N-dimethylaminomethyl-[1,1']-b iphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[2-Aminomethylphenyl]-3-cyano-6-[2'-methylsulfonyl-3-fluoro-[1,1']-biphen -4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[4-(1-methylimidazol-2'-y l)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2'-hydroxymethyl-3-fluoro-[1,1' ]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(ethoxycarbonyl)-6-[2'-N-pyrrolidinylmethyl-3-fluoro- [1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2'-N-pyrrolidinylmethyl-3-fluoro-[ 1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(aminocarbonyl)-6-[2'-(3-(R)-hydroxy-N-pyrrolidinylme thyl)-3-fluoro-[1,1' ]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-(N-formylaminomethyl)-6-[2'-methylsulfonyl-3-fluoro-[ 1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-(ethoxycarbonyl)-6-[2'-hydroxymethyl-[1,1'] -biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-(ethoxycarbonyl)-6-[2'-N-pyrrolidinylmethyl -[1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-[(imidazol-1-yl)methyl]-5-methyl-6-[(2'-N-pyrrolidiny lmethyl-[1,1']-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-[(tetrazol-1-yl)methyl]-5-methyl-6-[(2'-N-pyrrolidiny lmethyl-[1,1' ]-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[4-Methoxyphenyl]-3-[(tetrazol-2-yl)methyl]-5-methyl-6-[(2'-N-pyrrolidiny lmethyl-[1,1']-biphen-4-yl)]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3,5-dimethyl-6-[2'-N-dimethylaminomethyl-[1,1 ']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl-6-[2'-N,N-dimethylaminomethyl-[1,1'] -biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl-6-[2'-N-isopropylaminomethyl-[1,1']- biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl) methyl-[1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl-6-[4-(4,5-dihydroimidazol-1'-yl)phen yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl-6-[2'-N-(cyclopropylmethyl)aminometh yl-[1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl-6-[2'-N-pyrrolidinylmethyl-[1,1']-bi phen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl-6-[2'-(N-methyl-N-isopropyl)aminomet hyl-[1,1' ]-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3,5-dimethyl-[2'-(3-(R)-hydroxy-N-pyrrolidiny l)methyl-[1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-N,N-dimethylaminometh yl-[1,1']-biphen-4-yl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-N,N-dimethylaminometh yl-[1,1' 1-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrro lidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[4,3-d]-pyrim idin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl6-[4(2-methylimidazol-1'-yl)phenyl]-1 ,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; 1-[3-Aminobenzisoxazol-5'-yl]-3-methyl-6-[4-(2-(dimethylaminomethyl)imidazo l-1'-yl)-2-fluorophenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; and, 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[4-(2-(dimethylaminomethy l)imidazol-1'-yl)phenyl]-1,6-dihydropyrazolo-[4,3-d]-pyrimidin-7-one; or a pharmaceutically acceptable salt form thereof.

8. A pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

9. A pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt form thereof.

10. A pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 3 or a pharmaceutically acceptable salt form thereof.

11. A pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

12. A pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 5 or a pharmaceutically acceptable salt form thereof.

13. A pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 6 or a pharmaceutically acceptable salt form thereof.

14. A pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 7 or a pharmaceutically acceptable salt form thereof.

15. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

16. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt form thereof.

17. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 3 or a pharmaceutically acceptable salt form thereof.

18. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 4 or a pharmaceutically acceptable salt form thereof.

19. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 5 or a pharmaceutically acceptable salt form thereof.

20. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 6 or a pharmaceutically acceptable salt form thereof.

21. A method for treating a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of claim 7 or a pharmaceutically acceptable salt form thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc